Tonix Pharmaceuticals announces results from Phase 1 trial for TNX-1500

Tonix Pharmaceuticals (TNXP) announced positive topline results from its Phase 1, single ascending dose trial of TNX-1500 in healthy participants. The objectives of the Phase 1 trial were to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500, as well as to support dosing in a planned Phase 2 trial in kidney transplant recipients. Key highlights: TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 30 mg/kg i.v. doses; TNX-1500 showed mean half-life of 34-38 days for the 10 mg/kg and 30 mg/kg doses supporting monthly dosing for future efficacy trials; TNX-1500 was generally well-tolerated with a favorable safety profile.